Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Ratner

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Diabetes Care|January 31, 2006
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factorsBarbara V Howard, Lyle G Best, James M Galloway, et al.
Diabetes Care|January 28, 2009
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research GroupRonald B Goldberg, Marinella Temprosa, Steven Haffner, et al.
Diabetes|October 1, 2015
American Diabetes Association and JDRF Research Symposium: Diabetes and the MicrobiomeClay F Semenkovich, Jayne Danska, Tamara Darsow, et al.
The American Journal of Managed Care|April 3, 2013
Effectiveness and cost-effectiveness of diabetes prevention among adherent participantsWilliam H Herman, Sharon L Edelstein, Robert E Ratner, et al.
American Heart Journal|November 27, 2008
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristicsRobert E Ratner, Christopher P Cannon, Hertzel C Gerstein, et al.
The International Journal of Cardiovascular Imaging|March 2, 2011
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History)Héctor M García-García, Scot Garg, Salvatore Brugaletta, et al.
Diabetes Care|January 29, 2011
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargineKåre I Birkeland, Philip D Home, Ulrich Wendisch, et al.
Diabetes Care|June 6, 2014
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lisproJulio Rosenstock, Vivian A Fonseca, Jorge L Gross, et al.
Journal of Diabetes and Its Complications|July 22, 2011
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experienceMihriye Mete, Charlton Wilson, Elisa T Lee, et al.
Annals of Internal Medicine|January 4, 2006
Managing people at high risk for diabetesWilliam H Herman, Thomas J Hoerger, Katherine Hicks, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Diabetes Care|January 31, 2006
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factorsBarbara V Howard, Lyle G Best, James M Galloway, et al.
Diabetes Care|January 28, 2009
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research GroupRonald B Goldberg, Marinella Temprosa, Steven Haffner, et al.
Diabetes|October 1, 2015
American Diabetes Association and JDRF Research Symposium: Diabetes and the MicrobiomeClay F Semenkovich, Jayne Danska, Tamara Darsow, et al.
The American Journal of Managed Care|April 3, 2013
Effectiveness and cost-effectiveness of diabetes prevention among adherent participantsWilliam H Herman, Sharon L Edelstein, Robert E Ratner, et al.
American Heart Journal|November 27, 2008
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristicsRobert E Ratner, Christopher P Cannon, Hertzel C Gerstein, et al.
The International Journal of Cardiovascular Imaging|March 2, 2011
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History)Héctor M García-García, Scot Garg, Salvatore Brugaletta, et al.
Diabetes Care|January 29, 2011
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargineKåre I Birkeland, Philip D Home, Ulrich Wendisch, et al.
Diabetes Care|June 6, 2014
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lisproJulio Rosenstock, Vivian A Fonseca, Jorge L Gross, et al.
Journal of Diabetes and Its Complications|July 22, 2011
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experienceMihriye Mete, Charlton Wilson, Elisa T Lee, et al.
Annals of Internal Medicine|January 4, 2006
Managing people at high risk for diabetesWilliam H Herman, Thomas J Hoerger, Katherine Hicks, et al.
Pageof 9